Patent application number | Description | Published |
20080214531 | Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipdemia - Methods for the treatment of insulin resistance, diabetes, and/or diabetes associated dyslipidemia by administering niacin and meloxicam are disclosed. | 09-04-2008 |
20080275049 | Methods and Compositions for Upregulation of GATA Activity - A novel method of identifying compounds capable of upregulating GATA activity is disclosed. The method includes providing a sample of cells that express GATA, providing a sample of a candidate compound, contacting the cell sample and the compound sample, and measuring a quantitative indicator of GATA activity within the cell sample after the contacting step. GATA inducers identified by the method and uses therefore to upregulate GATA activity in subjects and to prevent or treat atherosclerosis or diabetes in subjects are also described. | 11-06-2008 |
20100297673 | METHODS AND COMPOSITIONS FOR UPREGULATION OF PEROXIREDOXIN ACTIVITY - A novel method of identifying compounds capable of upregulating Peroxiredoxin activity is disclosed. The method includes providing a sample of cells that express Peroxiredoxin, providing a sample of a candidate compound, contacting the cell sample and the compound sample, and measuring a quantitative indicator of Peroxiredoxin activity within the cell sample after the contacting step. Peroxiredoxin inducers identified by the method and uses therefore to upregulate Peroxiredoxin activity in subjects and to reduce LDL and/or VLDL levels and to prevent or treat atherosclerosis and inflammatory disorders such as arthritis in subjects are also described. The invention also provides a method of treatment of inflammatory and cardiovascular diseases which comprises providing a patient in need of treatment with an effective amount of a composition that increases Peroxiredoxin protein or activity. | 11-25-2010 |
20110097347 | Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad) - The present invention discloses (1) phenolic ester hybrids of niacin with m-methoxy-p-hydroxy phenyl compounds like eugenol, vanillin, apocynin, ferulic acid, isoferulic acid and eugenol epoxide and (2) cocrystals of hybrids as above, particularly cocrystal of niacin-eugenol hybrid with cocrystal former like eugenol and oxalic acid (3) novel pharmaceutical compositions comprising a combination of niacin and one or more small molecule/potentiating agent like eugenol, curcumin, cinnamic acid, meclofenamic acid, and their use in the treatment of a disorder or a disease caused by excess production of amyloid beta peptide-42 (Aβ42), its deposition, accumulation, and plaque formation including Alzheimer's Disease, dementia and mild cognitive impairment as well as other neurodegenerative diseases such as Parkinson's Disease and ischemic stroke. | 04-28-2011 |
20120322831 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) - Novel small molecule compounds for reduction of Aβ 42 production and for treatment of Alzheimer's Disease and other neurodegenerative disorders, methods of making them and pharmaceutical compositions containing them are described. | 12-20-2012 |
20130338199 | Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease - The present invention discloses (1) phenolic ester hybrids of niacin with m-methoxy-p-hydroxy phenyl compounds like eugenol, vanillin, apocynin, ferulic acid, isoferulic acid and eugenol epoxide and (2) cocrystals of hybrids as above, particularly cocrystal of niacin-eugenol hybrid with cocrystal former like eugenol and oxalic acid (3) novel pharmaceutical compositions comprising a combination of niacin and one or more small molecule/potentiating agent like eugenol, curcumin, cinnamic acid, meclofenamic acid, and their use in the treatment of a disorder or a disease caused by excess production of amyloid beta peptide-42 (Aβ42), its deposition, accumulation, and plaque formation including Alzheimer's Disease, dementia and mild cognitive impairment as well as other neurodegenerative diseases such as Parkinson's Disease, Huntington's disease, multiple sclerosis, amytrophic lateral sclerosis and ischemic stroke. | 12-19-2013 |
20140243282 | METHODS AND COMPOSITIONS FOR DESIGNING NOVEL CONJUGATE THERAPEUTICS - The present invention relates to novel drug conjugates, where in two drugs are linked together through an appropriate linker having at least two functional groups capable of forming covalent bond with drugs D1 and D2. The invention also relates to developing novel compositions, methods for their preparation and their use in treating various disease conditions. | 08-28-2014 |
20140322320 | NOVEL COMPOSITIONS FOR EMESIS CONTROL IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY AND METHODS THEREOF - A novel approach for emesis control in cancer patients undergoing chemotherapy using pharmaceutical formulations comprising a chemotherapeutic agent and anti-emetic agent(s) in combination with different and optimized release profiles is disclosed. | 10-30-2014 |
20140364457 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) - Novel small molecule compounds for reduction of Aβ 42 production and for treatment of Alzheimer's disease and other neurodegenerative disorders, methods of making them and pharmaceutical compositions containing them are described. | 12-11-2014 |